Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The LEADER trial with liraglutide and the REWIND trial with dulaglutide did not show significant increases in retinopathy complications, though differences in trial design, patient populations, baseline retinopathy prevalence, and rates of glycemic improvement may explain these discrepant findings
Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type 2 diabetes: a real-world 18-month prospective study
PMID 25184630
This can be useful for people who need a specific dosage or are allergic to certain ingredients in existing formulations
US$ 25.42
US$ 24.63
US$ 29.28
US$ 21.46
US$ 27.26
US$ 29.40
US$ 28.61
US$ 29.49
US$ 24.41
US$ 23.24
US$ 26.49
